<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Toxicity/intoxication</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>The ‘molecular revolution’ driving R&amp;D of new cancer therapeutics</title>
      <description>
        <![CDATA[“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at the Global Bio Conference in Seoul, South Korea Sept. 3.]]>
      </description>
      <guid>http://www.bioworld.com/articles/724032</guid>
      <pubDate>Tue, 09 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/724032-the-molecular-revolution-driving-r-and-d-of-new-cancer-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/GBC-Dennis-Slamon-9-4.webp?t=1757017348" type="image/jpeg" medium="image" fileSize="688131">
        <media:title type="plain">Dennis-Slamon speaks at GBC 25</media:title>
        <media:description type="plain">Dennis Slamon, chief of the division of hematology/oncology and director for the division of clinical/translation research at UCLA’s Jonsson Comprehensive Cancer Center, presents on investigating and verifying novel targets in oncology at GBC 2025 in Seoul, South Korea Sept. 3</media:description>
      </media:content>
    </item>
    <item>
      <title>The ‘molecular revolution’ driving R&amp;D of new cancer therapeutics</title>
      <description>
        <![CDATA[“New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at the Global Bio Conference in Seoul, South Korea Sept. 3.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723954</guid>
      <pubDate>Thu, 04 Sep 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723954-the-molecular-revolution-driving-r-and-d-of-new-cancer-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/GBC-Dennis-Slamon-9-4.webp?t=1757017348" type="image/jpeg" medium="image" fileSize="688131">
        <media:title type="plain">Dennis-Slamon speaks at GBC 25</media:title>
        <media:description type="plain">Dennis Slamon, chief of the division of hematology/oncology and director for the division of clinical/translation research at UCLA’s Jonsson Comprehensive Cancer Center, presents on investigating and verifying novel targets in oncology at GBC 2025 in Seoul, South Korea Sept. 3</media:description>
      </media:content>
    </item>
    <item>
      <title>South Korea forms new organoid consortium for nonanimal testing</title>
      <description>
        <![CDATA[South Korea’s Ministry of Food and Drug Safety (MFDS) launched a new industry-academia-research consortium to support the nation’s organoid industry, expected to grow in light of the U.S. FDA’s shift away from animal testing in the development of novel drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723658</guid>
      <pubDate>Tue, 26 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723658-south-korea-forms-new-organoid-consortium-for-nonanimal-testing</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Korea-organoid-hero-8-21.webp?t=1755810389" type="image/jpeg" medium="image" fileSize="854198">
        <media:title type="plain">K-Organoid Consortium group photo</media:title>
        <media:description type="plain">K-Organoid Consortium launching ceremony in Seoul, South Korea Aug. 13</media:description>
      </media:content>
    </item>
    <item>
      <title>South Korea forms new organoid consortium for nonanimal testing</title>
      <description>
        <![CDATA[South Korea’s Ministry of Food and Drug Safety (MFDS) launched a new industry-academia-research consortium to support the nation’s organoid industry, expected to grow in light of the U.S. FDA’s shift away from animal testing in the development of novel drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723543</guid>
      <pubDate>Thu, 21 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723543-south-korea-forms-new-organoid-consortium-for-nonanimal-testing</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Korea-organoid-hero-8-21.webp?t=1755810389" type="image/jpeg" medium="image" fileSize="854198">
        <media:title type="plain">K-Organoid Consortium group photo</media:title>
        <media:description type="plain">K-Organoid Consortium launching ceremony in Seoul, South Korea Aug. 13</media:description>
      </media:content>
    </item>
    <item>
      <title>South Korea forms new organoid consortium for nonanimal testing</title>
      <description>
        <![CDATA[South Korea’s Ministry of Food and Drug Safety (MFDS) launched a new industry-academia-research consortium to support the nation’s organoid industry, expected to grow in light of the U.S. FDA’s shift away from animal testing in the development of novel drugs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723276</guid>
      <pubDate>Thu, 21 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723276-south-korea-forms-new-organoid-consortium-for-nonanimal-testing</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2025/Korea-organoid-hero-8-21.webp?t=1755810389" type="image/jpeg" medium="image" fileSize="854198">
        <media:title type="plain">K-Organoid Consortium group photo</media:title>
        <media:description type="plain">K-Organoid Consortium launching ceremony in Seoul, South Korea Aug. 13</media:description>
      </media:content>
    </item>
    <item>
      <title>Elysium fields SOOPR overdose fix to fill opioid void</title>
      <description>
        <![CDATA[Elysium Therapeutics Inc. aims to tackle the problem of opioid overdose with a longer-lasting rescue agent that gets around the not-much-publicized problem of fentanyl rebound, or re-narcotization, which happens when the standard reverser wears off and the culprit drug stays active in the body, potentially killing the patient.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723390</guid>
      <pubDate>Fri, 15 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723390-elysium-fields-soopr-overdose-fix-to-fill-opioid-void</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Addiction-withdrawl-opioids.webp?t=1731686299" type="image/jpeg" medium="image" fileSize="678433">
        <media:title type="plain">Art concept for drug addiction</media:title>
      </media:content>
    </item>
    <item>
      <title>Elysium fields SOOPR overdose fix to fill opioid void</title>
      <description>
        <![CDATA[Elysium Therapeutics Inc. aims to tackle the problem of opioid overdose with a longer-lasting rescue agent that gets around the not-much-publicized problem of fentanyl rebound, or re-narcotization, which happens when the standard reverser wears off and the culprit drug stays active in the body, potentially killing the patient.]]>
      </description>
      <guid>http://www.bioworld.com/articles/723033</guid>
      <pubDate>Thu, 14 Aug 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/723033-elysium-fields-soopr-overdose-fix-to-fill-opioid-void</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Addiction-withdrawl-opioids.webp?t=1731686299" type="image/jpeg" medium="image" fileSize="678433">
        <media:title type="plain">Art concept for drug addiction</media:title>
      </media:content>
    </item>
    <item>
      <title>Diamedica’s DM-199 shows promise for serious pregnancy disorder</title>
      <description>
        <![CDATA[After expanding development of DM-199 (rinvecalinase alfa) into preeclampsia last year, Diamedica Inc. rolled out early phase II results showing the recombinant form of human tissue kallikrein-1 reduced the mother’s blood pressure, did not cross the placental barrier, and potentially improves blood flow to the fetus.]]>
      </description>
      <guid>http://www.bioworld.com/articles/722267</guid>
      <pubDate>Fri, 18 Jul 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/722267-diamedicas-dm-199-shows-promise-for-serious-pregnancy-disorder</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Sexual-health/Pregnancy.webp?t=1608060195" type="image/png" medium="image" fileSize="541206">
        <media:title type="plain">Pregnancy</media:title>
      </media:content>
    </item>
    <item>
      <title>Aimedbio’s ₩51B pre-IPO round to fuel new cancer ADCs</title>
      <description>
        <![CDATA[Samsung Medical Center spinoff Aimedbio Inc. announced raising ₩51.1 billion (US$37.15 million) in pre-IPO funding to advance its portfolio of clinical and preclinical antibody-drug conjugate (ADC) candidates.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720908</guid>
      <pubDate>Tue, 03 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720908-aimedbios-51b-pre-ipo-round-to-fuel-new-cancer-adcs</link>
    </item>
    <item>
      <title>China clears Mabwell’s Mailisheng injection to treat neutropenia </title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. on May 30 gained Chinese approval of Mailisheng (albipagrastim alfa; 8MW-0511) as a subcutaneous injection to treat febrile neutropenia induced by myelosuppressive anticancer treatment, such as radiotherapy and chemotherapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720906</guid>
      <pubDate>Tue, 03 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720906-china-clears-mabwells-mailisheng-injection-to-treat-neutropenia</link>
    </item>
    <item>
      <title>China clears Mabwell’s Mailisheng injection to treat neutropenia </title>
      <description>
        <![CDATA[Mabwell (Shanghai) Bioscience Co. Ltd. on May 30 gained Chinese approval of Mailisheng (albipagrastim alfa; 8MW-0511) as a subcutaneous injection to treat febrile neutropenia induced by myelosuppressive anticancer treatment, such as radiotherapy and chemotherapy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720868</guid>
      <pubDate>Mon, 02 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720868-china-clears-mabwells-mailisheng-injection-to-treat-neutropenia</link>
    </item>
    <item>
      <title>Aimedbio’s ₩51B pre-IPO round to fuel new cancer ADCs</title>
      <description>
        <![CDATA[Samsung Medical Center spinoff Aimedbio Inc. announced raising ₩51.1 billion (US$37.15 million) in pre-IPO funding to advance its portfolio of clinical and preclinical antibody-drug conjugate (ADC) candidates.]]>
      </description>
      <guid>http://www.bioworld.com/articles/720867</guid>
      <pubDate>Mon, 02 Jun 2025 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/720867-aimedbios-51b-pre-ipo-round-to-fuel-new-cancer-adcs</link>
    </item>
    <item>
      <title>Emris Pharma to develop topical drug to treat skin toxicities caused by EGFR inhibitor use in cancer</title>
      <description>
        <![CDATA[Emris Pharma, a recent spin-off of Hadasit Medical Research Services and Development Ltd. and Yissum Research Development Co., has started development of a new topical drug to treat skin toxicities caused by epidermal growth factor receptor (EGFR) inhibitors used to treat cancer.]]>
      </description>
      <guid>http://www.bioworld.com/articles/697806</guid>
      <pubDate>Fri, 09 Jun 2023 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/697806-emris-pharma-to-develop-topical-drug-to-treat-skin-toxicities-caused-by-egfr-inhibitor-use-in-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Epidermal-growth-factor-receptor-EGFR.webp?t=1670427251" type="image/png" medium="image" fileSize="1229566">
        <media:title type="plain">The epidermal growth factor receptor in the inactive (left) and active (right) form.</media:title>
      </media:content>
    </item>
    <item>
      <title>Discovery of novel ponatinib analogues with reduced cardiotoxicity</title>
      <description>
        <![CDATA[Researchers from Stanford University have published an article on the discovery of novel analogues of ponatinib that retained antitumor efficacy with substantially reduced cardiotoxicity.]]>
      </description>
      <guid>http://www.bioworld.com/articles/689633</guid>
      <pubDate>Wed, 14 Sep 2022 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/689633-discovery-of-novel-ponatinib-analogues-with-reduced-cardiotoxicity</link>
    </item>
    <item>
      <title>Acacia’s Barhemsys clears FDA hurdles, wins nod in PONV</title>
      <description>
        <![CDATA[LONDON – It was third time lucky for Acacia Pharma Group plc, as the FDA finally gave approval to Barhemsys (amisulpride) as a rescue treatment for surgical patients suffering postoperative nausea and vomiting (PONV), despite standard-of-care treatment.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433347</guid>
      <pubDate>Thu, 27 Feb 2020 11:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433347-acadias-barhemsys-clears-fda-hurdles-wins-nod-in-ponv</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Regulatory/FDA-approved-stamp3.webp?t=1591990896" type="image/png" medium="image" fileSize="172408">
        <media:title type="plain">FDA Approved stamp</media:title>
      </media:content>
    </item>
    <item>
      <title>Opioid epidemic taking a toll on drug development and patients</title>
      <description>
        <![CDATA[What with the lawsuits, declining prescriptions and approval hurdles that seem to be the U.S. answer to a nationwide opioid epidemic, drug companies have to think long and hard before spending the resources to develop yet another opioid drug. And patients are paying the price.]]>
      </description>
      <guid>http://www.bioworld.com/articles/433160</guid>
      <pubDate>Wed, 19 Feb 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/433160-opioid-epidemic-taking-a-toll-on-drug-development-and-patients</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Feb-2020/Ralph-Hudson-candid-Opioid-2-19.webp?t=1590608938" type="image/png" medium="image" fileSize="193807">
        <media:title type="plain">Ralph Hudson, veteran and director of the Arkansas Division of Labor</media:title>
        <media:description type="plain">Ralph Hudson, a veteran and director of the Arkansas Division
of Labor, knows the day is coming when he will no longer be able
to get the hydrocodone he uses to manage his pain when it gets
unbearable. Credit: Ralph Hudson</media:description>
      </media:content>
    </item>
    <item>
      <title>Cobra genome may yield new antivenoms, venom-based drugs</title>
      <description>
        <![CDATA[A reference genome from the Indian cobra compiled in an international collaborative study should lead to the development of new safer and more effective antivenoms, while the elucidated genome and predicted associated proteome may be a powerful platform for studies of venomous snakes.  ]]>
      </description>
      <guid>http://www.bioworld.com/articles/432228</guid>
      <pubDate>Tue, 07 Jan 2020 13:11:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432228-cobra-genome-may-yield-new-antivenoms-venom-based-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Jan-2020/Indian-Cobra-Science-1-6.webp?t=1590782493" type="image/png" medium="image" fileSize="274988">
        <media:title type="plain">Indian cobra </media:title>
        <media:description type="plain">Indian cobra (Naja naja). Credit: Somasekar Seshagiri;
photo by Rahul Alvares; edited by Allison Bruce</media:description>
      </media:content>
    </item>
    <item>
      <title>Cobra genome may yield new antivenoms, venom-based drugs</title>
      <description>
        <![CDATA[A reference genome from the Indian cobra compiled in an international collaborative study should lead to the development of new safer and more effective antivenoms, while the elucidated genome and predicted associated proteome may be a powerful platform for studies of venomous snakes.  ]]>
      </description>
      <guid>http://www.bioworld.com/articles/432192</guid>
      <pubDate>Mon, 06 Jan 2020 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/432192-cobra-genome-may-yield-new-antivenoms-venom-based-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2020/Jan-2020/Indian-Cobra-Science-1-6.webp?t=1590782493" type="image/png" medium="image" fileSize="274988">
        <media:title type="plain">Indian cobra </media:title>
        <media:description type="plain">Indian cobra (Naja naja). Credit: Somasekar Seshagiri;
photo by Rahul Alvares; edited by Allison Bruce</media:description>
      </media:content>
    </item>
    <item>
      <title>Emulate's Liver-Chip bests animal models in predicting toxicity in 8 drug candidates</title>
      <description>
        <![CDATA[Preclinical animal and cellular models are notoriously bad at predicting drug candidate toxicity in humans. Animal biology is often fundamentally different on this front than in humans, while cells in the lab can&#39;t be counted on routinely to replicate the bodily response.]]>
      </description>
      <guid>http://www.bioworld.com/articles/431030</guid>
      <pubDate>Fri, 08 Nov 2019 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/431030-emulates-liver-chip-bests-animal-models-in-predicting-toxicity-in-8-drug-candidates</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2019/Emulate-Organ-Chip-11-8.webp?t=1573508876" type="image/png" medium="image" fileSize="100033">
        <media:title type="plain">Emulate-Organ-Chip-11-8.png</media:title>
        <media:description type="plain">Organ-chip. Credit: Emulate Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>Thornhill's Clearmate device a breath of fresh air for victims of CO poisoning</title>
      <description>
        <![CDATA[]]>
      </description>
      <guid>http://www.bioworld.com/articles/429931</guid>
      <pubDate>Mon, 16 Sep 2019 00:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/429931-thornhills-clearmate-device-a-breath-of-fresh-air-for-victims-of-co-poisoning</link>
    </item>
  </channel>
</rss>
